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S TEROID RECEPTORS ARE hormone-activated transcription factors (1) controlling tissue-specific gene expression and a wide range of therapeutically important physiologies. Because of these properties, steroid receptors have been extensively studied at the level of gene expression (2) (3) (4) . Yet other modes of steroid receptor regulation must exist, with heretoforeunknown impacts on physiology, as most members of another: FK506-binding protein 52 (FKBP52), FKBP51, cyclophilin 40 (Cyp40) and protein phosphatase 5 (PP5). Because the Hsp90 dimer of receptor complexes generates only one TPR-acceptor site (6, 7) , at least four distinct heterocomplexes based on TPR protein content are possible for each steroid receptor. Although such heterogeneity implies differential function, almost nothing is known of how TPR proteins influence target cell responses to steroids. Indeed, a major unresolved question is whether all four TPRs contribute to the functioning of steroid receptors as a class, or whether individual TPRs preferentially regulate one receptor over another.
FKBP52 was the first TPR protein to be found with steroid receptors (8, 9) and the first to be cloned (10) . Its structure contains a C-terminal site for peptidyl prolyl cis/trans isomerase (PPIase) activity, as well as three centrally located TPR domains-highly degenerate 34-amino-acid sequences that mediate proteinprotein interactions (11) -that are the site of interaction with Hsp90 (12) (13) (14) . FKBP51 and Cyp40 share both of these domains with FKBP52, whereas PP5 shares only the TPR domain. FKBP52, FKBP51, and Cyp40 are also recognized as immunophilins, based on their ability to bind the immunosuppressive drugs FK506 and cyclosporine A (15) (16) (17) (18) (19) . PP5 is not known to have this function.
Although interaction of FKBP52 with PR and AR complexes in vitro has been long known (9, 20) , most functional studies of FKBP52 action have been for GR and point to a role for FKBP52 in both hormonebinding function and subcellular trafficking of this receptor. Transfection of FKBP52 into Saccharomyces cerevisiae (21) or overexpression in mammalian cells (22) caused potentiation of GR-mediated reporter gene expression that correlated with an increase in GR hormone-binding function. In the yeast system, a constitutively active GR mutant was not potentiated by FKBP52, suggesting that the effect is pretranscriptional. In most cells, the majority of FKBP52 is nuclear, but that fraction of FKBP52 found in the cytoplasm localizes to microtubules and is found to copurify with dynein (23, 24) . The dynein/FKBP52 interaction occurs at the PPIase domain, suggesting that FKBP52 serves as an adaptor between dynein and the GR/Hsp90 complex that binds at the TPR-domain (7, 25) . Indeed, a recent study by the Rein group (26) showed that the PPIase domain of FKBP52 is essential for both dynein interaction and hormone-induced translocation of the GR. Additional evidence for a role in translocation has been provided by a switching mechanism in which hormone causes displacement of FKBP51 by FKBP52 in GR complexes, leading to corecruitment of dynein and movement of the newly formed GR/Hsp90/ FKBP52 complex to the nucleus of intact cells (27) . Thus, it is now likely that differential incorporation of TPR proteins into steroid receptor complexes may form the basis for selective control of hormone binding, subcellular trafficking, and, perhaps, other functions of steroid receptors.
To establish the relevance of these in vitro observations to physiological actions of steroid receptors, we generated FKBP52-deficient (Ϫ/Ϫ) mice. Surprisingly, no overt defects of GR-controlled physiology have been seen in these animals. Instead, the principal defect appears to be reduced fertility in males and sterility in females. Male infertility results from hypospadias due to compromised activity on the part of AR during development-a result that is highly similar to a recent report from the Smith laboratory (28) , in which researchers have independently established FKBP52 (Ϫ/Ϫ) mice. In this work, we analyze the underlying causes of sterility in FKBP52 (Ϫ/Ϫ) females and show that it principally arises from a failure of implantation at the uterus due to compromised activity by the progesterone receptor A isoform (PR-A).
RESULTS

Targeted Disruption of FKBP52 Leads to Female Sterility
We generated FKBP52-deficient mice through targeted disruption of the FKBP52 gene at exons 2-5 ( Fig. 1A) . Genomic Southern blot and PCR analyses were used to genotype targeted embryonic stem (ES) cells and mutant mice (Fig. 1, B and C) . Northern blot and Western blot analyses confirmed that FKBP52 expression was absent in FKBP52-deficient mice (Fig.  1, D and E). Heterozygous (ϩ/Ϫ) mice were viable and fertile and were intercrossed to obtain homozygous (Ϫ/Ϫ) mutants. Male and female homozygous (Ϫ/Ϫ) mutants were equally presented in the litters and developed to adulthood.
By breeding to (ϩ/ϩ) males, FKBP52-deficient females were found to be sterile, whereas fertility of (ϩ/Ϫ) females was unimpaired (Table 1) . To determine the cause of infertility, a series of morphological and histological analyses were performed on (Ϫ/Ϫ) ovaries and uteri. There were no apparent developmental abnormalities in these reproductive organs (data not shown), suggesting that FKBP52 is not required for their normal development. Mutant females had normal estrous cycles and could be plugged by wild-type (WT) male mice.
Failure of Progesterone-Mediated Implantation in FKBP52 ؊/؊ Females
When FKBP52 (Ϫ/Ϫ) females were mated with WT males, no implanted embryos could be found at embryonic d (E) 6.5 of development ( Fig. 2A) . However, FKBP52 (Ϫ/Ϫ) females or superovulated (Ϫ/Ϫ) females mated to WT males did result in the presence of four-cell stage embryos in the oviducts (data not shown), implicating a failure of zygote implantation as the primary reason for sterility. To test this, we performed uterus-transfer experiments in which (ϩ/ϩ) blastocysts were implanted into uteri of pseudopreg-nant FKBP52 (Ϫ/Ϫ) and (ϩ/ϩ) females (Fig. 2B) . Seventeen embryos (E8.5) of 26 transferred blastocysts were recovered from (ϩ/ϩ) females, but not a single embryo was found (normal or abnormal) of 32 blastocysts transferred to the (Ϫ/Ϫ) females, a strong indication that uteri of FKBP52-deficient females are not able to support implantation. These observations are consistent with recent work from Dey's group (29) describing an independent FKBP52 KO strain.
Based on these results, we reasoned that uterine insensitivity to progesterone, estrogen, or both may be the reason for implantation failure. To assess the response to estrogens, ovariectomized FKBP52 (Ϫ/Ϫ) and (ϩ/ϩ) females were challenged with 17␤-estradiol for 5 d. Although there was a slight trend of decreased uterine weight gain in response to estrogen (Fig. 3A) , the difference between FKBP52 (Ϫ/Ϫ) and (ϩ/ϩ) females did not reach statistical significance, suggesting that the uterine response to estrogen in FKBP52-deficient females is largely normal. To assess the response to progesterone, decidualization experiments were performed on uteri from ovariectomized females. In contrast to the estrogen response, the results show a dramatic failure of decidualization by the (Ϫ/Ϫ) females in response to progesterone and implantation trauma (Fig. 3 , B and C), suggesting a strong inhibition of progesterone responsiveness in FKBP52 (Ϫ/Ϫ) females.
Partial Disruption of Ovulation and Mammary Gland Alveologenesis in FKBP52 (؊/؊) Females
The previously described results suggested that loss of FKBP52 in females primarily affected PR activity, at least in the uterus. To test the involvement of FKBP52 in other PR-regulated tissues, we assessed responses to progesterone in the ovary and mammary. Superovulation experiments were performed to measure ovulation competency by treating virgin (3 to 4 wk old) females with gonadotropins, followed by flushing of oocytes from the oviduct (Fig. 4A) . Significantly fewer oocytes from pregnant mare serum gonadotropin/human chorionic gonadotropin (hCG)-treated FKBP52 (Ϫ/Ϫ) females were obtained compared with agematched littermate (ϩ/ϩ) females (17 vs. 27 oocytes per female, respectively), suggesting that reduced ovulation is a contributory factor in the sterility phenotype of (Ϫ/Ϫ) females. Because this same test has been used in PR knockout (PRKO) mice to establish the essential role of PR in normal ovulation (30), we can conclude that PR activity in the ovary is partially dependent on FKBP52. Mammary gland ductal development in the FKBP52 (Ϫ/Ϫ) animals was measured in response to administration of 17␤-estradiol and progesterone for 14 d after ovariectomy. There was a moderate reduction in mammary gland tertiary side branching and alveologenesis in FKBP52-deficient females compared with WT controls (Fig. 4B ). Like ovarian function, PRKO females have been used to show an essential role for PR in pregnancy-induced tertiary side branching (mimicked by estrogen and progesterone administration) (31). Thus, for both ovulation and mammary gland differentiation, it appears that FKBP52 contributes but is not essential to steroidal activity at these organs.
Progesterone Failure in the Uterus of FKBP52 (؊/؊) Females Is Selective for the PR-A Isoform
PRs exist as two isoforms, PR-A and PR-B, with each isoform playing a critical but distinct role in uterine, ovarian, and mammary gland function (32) . The work of the Conneely laboratory has shown PR-B to be the essential isoform mediating response to progesterone in the mammary (33), whereas PR-A is essential to ovarian and uterine functions (34) . Based on our results, it therefore appears that the FKBP52-deficient female more closely resembles the PR-A-deficient (PRAKO) rather than the PR-B-deficient female, suggesting that FKBP52 may preferentially regulate the PR-A isoform in vivo. An alternative explanation, however, is that activities of both PR isoforms are controlled by the tissue expression profile of FKBP52. In other words, PR activity in the FKBP52-deficient female should inversely correlate with the expression levels of FKBP52 in WT animals. We have measured FKBP52 protein expression in various tissues (Fig. 5 ).
(FKBP52 expression in the mammary is missing from this analysis due to the difficulty of selectively excising this tissue.) About equal levels of FKBP52 were found in the uterus and ovary of WT females. Thus, expression levels of FKBP52 do not explain the tissue-specific differences seen in PR activities in the FKBP52 (Ϫ/Ϫ) females. The above-described results suggest that FKBP52 control of PR action may be both receptor and tissue specific. To directly test the receptor specificity of FKBP52 in the uterus, we asked whether ablation of FKBP52 only blocked PR-A signaling. This was done by measuring expression of uterine genes controlled by PR-A, PR-B and ER (Fig. 6 ). Calcitonin (Ct) and amphiregulin (Ar) are two PR-A targets that are upregulated in uterus at implantation (third day postfertilization after plug) (34) (35) (36) . Histidine decarboxylase (Hdc) is PR-B target that is also up-regulated in uterus at implantation (34, 37) . Lactoferrin (Lf) is a known target of ER that is expressed in uterus at the preimplantation stage and is quickly down-regulated during implantation (38) . As shown in Fig. 6A , the expression patterns of Lf and Hdc were normal in FKBP52-deficient uterine tissues. Only the Ct and Ar genes were affected by FKBP52 deficiency, showing no detectable expression levels in FKBP52-deficient uteri at the implantation stage. Lack of Ct and Ar expression was not due to reduced expression of PR-A, because normal levels of both PR-A and PR-B were detected in the uterus of (Ϫ/Ϫ) females (Fig. 6B) . Thus, FKBP52 appears to be essential for PR-A activity at the uterus, but not for ER or its closely related isoform PR-B.
Preferential Association of FKBP52 with Uterine PR-A Compared with PR-B and No Effect of FKBP52 Loss on PR Hormone-Binding Function
As an additional test of the specificity model, we reasoned that selective regulation of PR-A over PR-B by FKBP52 would have to mean preferential association of FKBP52 with PR-A. To test this, we performed sequential coimmunoprecipitation of PR-B followed by PR-A complexes from WT and FKBP52-deficient uterine lysates (Fig. 7A) . The first immunoprecipitation used an antibody specific to PR-B (PR-6), followed by a second immunoprecipitation of the PR-B-cleared uterine lysates with antibody reactive to PR-A/B (C-19). Samples were resolved on a single SDS-PAGE gel, transferred to Immobilon membrane, and then the membrane was cut at the 66-kDa marker. Detection of the PRs (top half of membrane) was done by blotting with the C-19 antibody, making it possible to quantify relative yields of each PR isoform. Detection of FKBP52 (bottom half) was done with the HSP56 antibody. After blotting, the membrane halves were reassembled and exposed to film. This procedure resulted in a selective and approximately equal purification of each PR isoform from both the WT and FKBP52-deficient uterine lysates (Fig. 7, A and B) . Interestingly, the amount of receptor-associated FKBP52 in the WT lysates was greater for PR-A than for PR-B. Thus, a preferential interaction of FKBP52 with PR-A appears to occur, as predicted by the receptor specificity model. Although both PR isoforms interacted with Hsp90 in WT uterine lysates (data not shown), we tested whether loss of FKBP52 leads to disruption of the PR-A/Hsp90 interaction. This was done by blotting for PR-A-associated Hsp90 in the WT and FKBP52-deficient uterine lysates (Fig. 7C) . Results showed levels of Hsp90 to be unchanged. Because of the link between FKBP52 and ability of GR to bind hormone (21, 22), we measured PR hormone-binding function in whole and PR-B-cleared uterine lysates. There were no significant differences between WT and knockout animals with respect to binding sites, dissociation constants, or EC 50 values using both [ 3 H]R5020 or [ 3 H]progesterone (see Fig. 8 for a representative result). Thus, the uterine forms of PR-B and PR-A appear to have normal hormone-binding function in the absence of FKBP52.
Analysis of PR and ER Transcriptional Activities in (؉/؉) and (؊/؊) Mouse Embryonic Fibroblasts (MEF)
Because loss of FKBP52 had no affect on the hormone-binding function of PR-A, the major role of FKBP52 must be downstream of this function. To better measure the effect of FKBP52 on PR-A transcriptional activity, we established MEF cell lines from WT and FKBP52-deficient embryos (Fig. 9A) . The MEF cells were transfected with expression constructs for mouse PR-A, mouse PR-B, and human ER␣ ( approximately 40% activity remaining. A similar result was found for ER␣, for which approximately 50% activity remained at an ERE-Luc reporter in the (Ϫ/Ϫ) MEF cells (Fig. 9C) . We speculate that partial abrogation of PR-B and ER␣, as seen in the MEF cells, may form the basis for partial losses of ovary and mammary gland function seen in vivo. Because PR-A activity at the MMTV promoter was weak, we retested PR-A activity in the MEF cells using a PRE-Luc construct (Fig. 9D) . This construct yielded much better activity for PR-A in the WT cells, and once again there was a dramatic loss of activity in the KO cells. To eliminate any potential nonspecific effect of the KO MEF cells on PR-A activity, we reexpressed FKBP52 in the knockout cells, and the results show a near-complete rescue of PR-A activity in these cells (Fig. 9D ). Taken as a whole, the MEF transcriptional studies suggest that FKBP52 exerts relative, rather than absolute, effects on the activities by the PR isoforms and ER. As elaborated in the Discussion, we propose that these results are consistent with the range of reproductive phenotypes seen in the (Ϫ/Ϫ) females.
DISCUSSION
In recent years, the complexity of steroid receptor heterocomplexes based on TPR protein content has become apparent. This heterogeneity has contributed to two major competing hypotheses. Either all receptors are regulated (perhaps in distinct ways) by all four TPR proteins (FKBP52, FKBP51, Cyp40, and PP5), or some receptors are preferentially regulated by one TPR protein but not another. In this work, we provide evidence for the latter hypothesis through use of mice with targeted ablation of FKBP52. We show that FKBP52 plays an essential but receptor-specific role in female reproductive physiology. In particular, FKBP52 was found to selectively regulate the activity of PR-A in the uterus, while having a lesser role in the activity of PR-B or ER␣ in this tissue. At both ovary and mammary, loss of FKBP52 had a moderate effect on ovulation rates and ductal side branching, respectively, suggesting that FKPB52 plays a contributory but not essential role in steroidal responses at these tissues.
We believe that key aspects of our data allow us to make the above-described conclusion. First, absence of FKBP52 leads to female sterility due to a selective failure of implantation (Fig. 2) . Implantation failure was not due to a lack of estrogen stimulation (Fig. 3A) . Rather, it resulted from an inability of the uterus to mount a decidualization response to progesterone (Fig. 3B) -a process known to be regulated by PR-A (34). Evidence for selective control of PR-A over PR-B by FKBP52 was provided by the observation that only PR-A-regulated genes were affected in the uterus (Fig.  6 ) and that uterine PR-A receptors showed a preferential ability to interact with FKBP52 (Fig. 7) . Lastly, studies in MEF cells showed a near-complete loss of PR-A transcriptional activity at heterologous reporters, whereas activities of PR-B and ER␣ were partially affected (Fig. 9 ). On this last point, one could legitimately wonder why partial loss of PR-B and, especially, ER␣ transcriptional activity should have no apparent affect on physiology in the uterus. One possibility is that half-transcriptional activity can be phenotypically neutral in the same way as half-gene dosage in heterozygotes is often neutral. For example, our (ϩ/Ϫ) females show half-dosage for FKBP52 RNA (Fig. 1D ) and protein (data not shown), yet demonstrate no alteration in fertility (Table 1) . On the other hand, partial loss of PR-B or ER␣ transcriptional activity may actually provide the basis for the partial responses seen in the mammary and ovary of the FKBP52-deficient female (Fig. 4) . To reconcile these possibilities, transcriptional studies must move away from the generic MEF cells and reporter genes to WT and knockout cell lines derived from the affected tissues (uterus, ovary, mammary) and the measurement of key endogenous genes. In this way, the actual extent to which FKBP52 controls PR-A, PR-B, and ER␣ activities in each tissue can be determined. With the seminal work of Lydon et al. (30) , in which genetic ablation of PR (A and B isoforms) was achieved to yield PRKO mice, the role of PR in reproductive physiology has become increasingly apparent. This work showed PR to be essential to reproductive responses at the uterus, ovary, and mammary as well as to sexual behavior. More recent work by Conneely and co-workers (34) has shown PR-A and PR-B to play distinct roles in these responses. For example, PRAKO mice were sterile, primarily due to a complete lack of implantation and a marked reduction in ovulation. PRAKO females, however, were normal with respect to hormone-induced ductal side branching and lobuloalveologenesis at the mammary. In contrast, PR-Bdeficient females were fertile but showed greatly diminished mammary gland development in response to progesterone (33) . Based on these reports, it appears that our FKBP52 (Ϫ/Ϫ) females show a strong resemblance to PRAKO animals. Although the FKBP52 (Ϫ/Ϫ) females have a moderately reduced mammary response to progesterone (Fig. 4B) , they do show a complete failure of implantation (Fig. 2) and have uteri that are unable to mount a decidual response to hormone (Fig. 3) , as also reported for PRAKO (34) . In the PRAKO female, ovulation was strongly reduced (but not eliminated), whereas the FKBP52 (Ϫ/Ϫ) animals showed a moderate but significant reduction for this parameter. On this point, our results differ in degree, but not, we would argue, with respect to overall physiology. Additional evidence for this conclusion can be found in the PR-and ER-regulated genes of the uterus. Ct and Ar are two genes identified by Conneely and colleagues (34) as being regulated by PR-A. Expression of both of these genes was abrogated in FKBP52 (Ϫ/Ϫ) uteri on d 3 of pseudopregnancy (Fig. 6A) . Conversely, genes controlled by PR-B (Hdc) and ER␣ (Lf) were unaffected (Fig. 6A) . Interestingly, our data also support the claim of Conneely's group that progesterone-mediated repression of ER during the early stages of implantation is mediated by PR-B (34), as loss of lactoferrin expression at d 3 of pseudopregnancy was observed in the FKBP52 (Ϫ/Ϫ) uteri. Thus, uterine PR-B in the FKBP52 (Ϫ/Ϫ) females must be active with respect to this function.
Although our results are consistent with those of Conneely and colleagues, a variety of reports have proposed PR-A to be the principal isoform responsible for inhibition of ER and other steroid receptors. The McDonnell group (40) (41) (42) , in particular, has shown that ligand-activated PR-A can inhibit the transcriptional activities of ER␣, PR-B, GR, AR, and mineralocorticoid receptor, whereas PR-B has no such activity. Interestingly, this inhibition is promoted by both agonist and antagonist and does not require a functional DNAbinding domain, suggesting that PR-A-mediated repression acts by a distinct pathway from that which controls its own transactivation function. Why our results and those of Conneely and colleagues should differ from those of the McDonnell laboratory is not clear. One possible explanation is that the inhibitory activity of PR-A is not universal but tends to occur in cell lines (e.g., mammary-derived MCF cell lines) where PR-A transcriptional activity is not active (40) . Conneely and colleagues have clearly shown that PR-A has potent and selective transcriptional activity in uterine epithelial cells (34) . Thus, in these cells the repressive activity may fall to PR-B. An alternative explanation in our system is that loss of FKBP52 only affects the transcriptional function of PR-A, leaving it free to repress ER␣ via its transrepressive function. We propose that proper resolution of these issues will require a thorough examination of the transactivation and transrepressive functions of each PR isoform in uterine epithelial cell lines derived from FKBP52 (ϩ/ϩ) and (Ϫ/Ϫ) females.
Our results have uncovered two interesting but unresolved issues concerning the role of FKBP52 in control of steroid receptor action in vivo. First, recent studies suggest that FKBP52 has a positive effect on the ability of glucocorticoid receptor to bind hormone (21, 22) . In contrast, the closely related TPR FKBP51 has the opposite effect of depressing GR hormonebinding ability and its subsequent transactivation function (26, 43, 44) . Thus, we were surprised to find that loss of FKBP52 did not affect the ability of PR-A or PR-B to bind hormone (Fig. 8) . A simple explanation may be that control of hormone-binding function by FKBP52 applies to some receptors (GR) but not others (PR). Alternatively, this effect may be tissue or celltype dependent. In support of this, we (data not published) and others (28) have found that AR hormonebinding function is also not affected by FKBP52 loss. Yet, it is also true that the studies showing potentiation of GR hormone-binding function have relied on overexpression of FKBP52. Thus, if FKBP51, but not FKBP52, determines the basal level of this function, then down-regulation or knockout conditions for FKBP52 may have little or no effect. The second issue concerns our observation that FKBP52 loss seems to have a major effect in the uterus but only a moderate effect in the ovary. Conneely and colleagues have shown PR-A to be essential to ovulation rates, but our results suggest that FKBP52 plays a less essential role in PR-A activity in this organ. If so, then it is possible that another TPR may be the preferred cochaperone of PR-A in the ovary. Our Western blot analysis (Fig. 5) shows that all four TPRs (FKBP52, FKBP51, Cyp40, and PP5) are expressed in the ovary, and that two of these (FKBP51 and Cyp40) exist at higher levels in the ovary compared with the uterus. Thus, it will be interesting to see whether genetic ablation of another TPR leads to a more dramatic phenotype at this organ. Indeed, a broader conclusion we can draw from our study is that FKBP52 is not the primary TPR regulating ER␣ or PR-B in vivo, suggesting that similar studies on the other TPRs may lead to alterations in ER␣-or PR-B-controlled physiology.
Recently, Tranguch et al. (29) made mice deficient in FKBP52 and showed that this protein plays an essential role in PR-mediated uterine receptivity to implantation, but they were not able to discriminate between PR-A and PR-B actions. We believe that our work provides an important advancement by showing that FKBP52 is essential to female reproductive physiology by primarily controlling the actions of PR-A in the uterus. Abrogation of PR-A activity at this organ through FKBP52 loss leads to a complete failure of implantation, while leaving other PR-regulated tissues only moderately affected. Thus, FKBP52 is now a potential target for development of nonsteroidal birthcontrol drugs that avoid a myriad of estrogen-and progestin-based side effects. Of broader significance is the fact that other TPR proteins (e.g. FKBP51, Cyp40, and PP5) are known to act as steroid receptor cochaperones. Because of the receptor and tissue selectively uncovered for FKBP52, it is now likely that each TPR will have a distinct profile of receptor-and tissue-specific actions, providing many new opportunities for selective intervention in steroid-based disease and physiology. 
MATERIALS AND METHODS
Targeted Deletion and Generation of FKBP52-Deficient Mice
A FKBP52 genomic clone was isolated from a mouse 129SvEv genomic bacterial artificial chromosome library (RPCI-22 129 mouse library from BACPAC Resources, Children's Hospital Oakland, Oakland, CA). The mouse FKBP52 gene contains 10 exons (Fig. 1A) . Linearized targeting vector (25 ng) was electroporated into ES cells (CCE916 ES cell line), clones were selected in G418 and gancyclovir, DNA from the clones was analyzed by Southern blot, and targeted ES cell lines FK52-A22 and FK52-E14 were expanded and injected into blastocysts. Male chimeras were bred to C57BL/6J or 129SvEv females to generate F1 offspring. Mutant mice generated from both targeted ES cell lines had identical phenotypes. Genotypes were determined by either Southern blot or PCR analyses. Primer sequences for FKBP52 genotyping were as follows: neo1, TGCCGCGCTGTTCTCCTCT; neo2, AAGCGGCCATTTTCCACCAT; fkbp52 forward, CTAAGC-CATGGGGTGGAGATGTG; fkbp52 reverse, AAAGCTCT-TCAGCCGCACTTCATAC. We also used PCR analysis of the sry gene to determine gender of the embryos. Primer sequences for sry genotyping are as follows: forward primer, GACTAGACATGTCTTAACATCTGTCC; reverse primer, CCTATTGCATGGACTGCAG CTTATG. All animal experiments were carried out using a protocol approved by the Indiana University School of Medicine Institutional Animal Care and Research Advisory Committee.
Morphological and Histological Analyses
We examined the morphology and histology of multiple tissues and organs from female FKBP52-deficient mice and age-matched littermate controls. Isolated tissue samples were fixed in 10% neutral-buffered formalin, paraffin embedded, sectioned (5 m), and stained with hematoxylin and eosin.
Assessment of Hormonal Response
To assess the ovulatory function in FKBP52-deficient females, virgin females (3-4 wk of age) were superovulated by administration of 5 IU of pregnant mare serum gonadotropin (Diosynth, Chicago, IL) and followed by 5 IU of hCG (Pregnyl; Organon, Inc., West Orange, NJ) after 48 h to induce ovulation. Oocytes were harvested from oviducts 24 h after hCG administration.
To determine estrogen response in mice, WT and FKBP52 (Ϫ/Ϫ) females (8 wk old) were subjected to an estrogen regimen 10 d after ovariectomy. Briefly, mice were primed for 5 d (d 11, 12, 13, 14, and 15) with sc injections of 100 ng 17␤-estradiol in 0.1 ml sesame oil. Six hours after the fifth injection, uteri were dissected and weighed.
The decidualization response was performed as previously described (45) . In brief, ovariectomized WT and FKBP52-deficient females (8 wk of age) were administered in three continuous days with sc injections of 100 ng of 17␤-estradiol (Sigma, St. Louis, MO) (dissolved in sesame oil), followed by 2 d without hormone treatment before another 3-d course of hormone administration with progesterone (1 g/d) and 17␤-estradiol (6.7 ng/d). Six hours after the third hormone injection, one horn of the uterus was traumatically stimulated by insertion of a burred needle into the uterus horn just proximal to the cervix and longitudinally scratching the entire length of the uterine horn. Another side of horn was not stimulated. Daily injections of progesterone were administered until 6 d after stimulation. The uteri were isolated, and the matched horns were cut to equal lengths and weighed.
Northern Blot Analysis of Uterine Genes
Total RNA was extracted from kidney and uteri with the Trizol RNA kit (Invitrogen Corp., Carlsbad, CA). Total RNA (20 g) was denatured, separated by formaldehyde-agarose gel electrophoresis, transferred to nitrocellulose membrane, and cross-linked by UV irradiation (Spectrolinker; Spectronics Corp., Westerbury, NY). cDNA fragments for probe (mouse FKBP52, Ct, Ar, Hdc, and Lf) were initially generated via RT-PCR and confirmed by sequence analysis. Standard hybridization and washing procedures were used throughout.
Immunoprecipitation of PR-A and PR-B Uterine Heterocomplexes
Several uteri (4) from females of each genotype were pooled before tissue homogenization in 50 mM phosphate buffer, 20 mM sodium molybdate, 10% glycerol (pH 7.4) with protease inhibitor cocktail (Sigma, P2714) using a tissue disruptor (Tissue Tearor; BioSpec Products, Inc., Bartlesville, OK). Lysates were centrifuged at 100,000 ϫ g for 60 min and used fresh, without freezing or storage. The (ϩ/ϩ) and (Ϫ/Ϫ) lysates were first immunoadsorbed to protein A-Sepharose in the complete absence of antibody to clear the lysates of FKBP52 that nonspecifically bound the resin. The cleared lysates were then immunoadsorbed to protein A-Sepharose with PR-6 antibody specific to PR-B (MA1-411; Affinity Bioreagents, Golden, CO) and corresponding nonimmune IgG as control. The same lysates (supernatants) were then immunoadsorbed a third time with appropriate nonimmune IgG control or C-19 antibody recognizing both PR-A and PR-B (SC-538; Santa Cruz Biotechnology, Santa Cruz, CA) to purify the remaining PR-A isoform. Samples were resolved on a single SDS-PAGE gel and Western blotted using C-19 antibody to detect PR-A and PR-B, HSP56 antibody (PA3-020; Affinity Bioreagents) against FKBP52, or F-8 antibody (SC-13119; Santa Cruz Biotechnology) against Hsp90. It should be noted that use of C-19 antibody for the blotting step made it possible to measure relative yields of PR-A and PR-B, even though two distinct antibodies were used for the purification step. Western blotting was achieved in denaturing sodium dodecyl sulfate gels (3), using a 7-14% acrylamide gradient to achieve maximal separation between FKBP52 and antibody heavy chains. Transfer of the samples to Immobilon-P membranes (Millipore Corp., Bedford, MA) and quantitative immunoblotting were performed as previously described (4, 5) , using appropriate 125 I-conjugated counter antibodies, followed by autoradiography and densitometric scanning. Images provided in Fig. 7 were derived from a single autoradiogram film each for WT and knockout coimmunoprecipitations, ensuring equal exposure time for measurement of PRA, PRB, and FKBP52 yields.
PR Hormone Binding Assay
Lysates from WT and FKBP52-deficient uteri were prepared as described above. The lysates were used for the binding assay without freezing. Both saturation and competition assays were performed using [ 3 H]P4 or [ 3 H]R5020. In each case, binding was allowed to occur for 20 h on ice. Nonspecific binding was determined in the presence of excess unlabeled hormone. Protein-bound radioactivity was isolated using 1% dextran-coated charcoal in 10 mM HEPES buffer (pH 7.4). Specific binding was normalized for protein content. Results shown in Fig. 8 represent a one-site competition analysis (GraphPad Prism software; GraphPad, San Diego, CA) using [ 3 H]R5020.
Reporter Gene Assays in MEF Cells
MEFs were isolated from WT and FKBP52 knockout E13. . MMTV-CAT and PRE-Luc reporter constructs were used to assay for both PR-A and PR-B activity, whereas an ERELuc reporter was used for ER. CAT enzyme activity was measured by the method Nordeen et al. (47) using [ 3 H]acetylcoenzyme A as substrate, whereas Luc activities were measured using a commercial kit (Promega, Madison, WI). All values were normalized for transfection efficiency by cotransfection with a cytomegalovirus-driven galactosidase reporter.
